Skip to main content
Top
Published in: International Journal of Clinical Oncology 1/2013

01-02-2013 | Original Article

Prognostic factors for patients with solitary bone metastasis

Authors: Manabu Hoshi, Jun Takada, Makoto Ieguchi, Shinji Takahashi, Hiroaki Nakamura

Published in: International Journal of Clinical Oncology | Issue 1/2013

Login to get access

Abstract

Background

The term ‘solitary bone metastasis’ is defined in the present study as a single bone metastasis originating from a primary cancer without visceral organ metastasis. We assessed the survival rates and prognostic factors in 42 patients with solitary bone metastasis, and discussed the impact of different surgical strategies on survival.

Methods

We retrospectively analyzed data from 42 patients (25 male, 17 female) who underwent treatment for solitary bone metastasis at a single institution. The median age of the patients was 64.5 years (range 41–82 years). The patients were followed for an average period of 21.2 months (range 0.4–127.3 months). Their clinical records were retrospectively reviewed. Factors influencing survival were determined using univariate and multivariate analyses; particular attention was paid to the orthopedic surgery used for solitary bone metastasis.

Results

The 1-year survival rate was 76.5%, and the median survival period was 30.0 months. The presence of primary cancer and poor performance status were identified as independent prognostic factors using Cox regression multivariate analysis. Tumor resection and surgical margin were not significantly related to patient survival.

Conclusions

The results of this analysis indicated that the prognosis for patients with solitary bone metastasis depended on the presence of primary cancer and on poor performance status.
Literature
1.
go back to reference Tofe AJ, Francis MD, Harvey WJ (1975) Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 16:986–989PubMed Tofe AJ, Francis MD, Harvey WJ (1975) Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 16:986–989PubMed
2.
go back to reference Katagiri H, Takahashi M, Wakai K et al (2005) Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698–703PubMedCrossRef Katagiri H, Takahashi M, Wakai K et al (2005) Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698–703PubMedCrossRef
3.
go back to reference Tokuhashi Y, Matsuzaki H, Toriyama S et al (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113PubMedCrossRef Tokuhashi Y, Matsuzaki H, Toriyama S et al (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113PubMedCrossRef
4.
go back to reference Tomita K, Kawahara N, Kobayashi T et al (2001) Surgical strategy for spinal metastases. Spine 260:298–306CrossRef Tomita K, Kawahara N, Kobayashi T et al (2001) Surgical strategy for spinal metastases. Spine 260:298–306CrossRef
5.
go back to reference Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
6.
go back to reference Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562PubMed Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562PubMed
7.
8.
9.
go back to reference Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMed Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMed
10.
go back to reference Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736PubMedCrossRef Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736PubMedCrossRef
11.
go back to reference Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246PubMedCrossRef Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246PubMedCrossRef
12.
go back to reference Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032–3037PubMedCrossRef Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032–3037PubMedCrossRef
13.
go back to reference Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61:3–13PubMedCrossRef Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61:3–13PubMedCrossRef
14.
go back to reference Cho HS, Oh JH, Han I et al (2009) Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. J Bone Joint Surg Br 91:1505–1512PubMedCrossRef Cho HS, Oh JH, Han I et al (2009) Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. J Bone Joint Surg Br 91:1505–1512PubMedCrossRef
15.
go back to reference He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2712PubMedCrossRef He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2712PubMedCrossRef
16.
go back to reference Chan KM, Yu MC, Wu TJ et al (2009) Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 15:5481–5488PubMedCrossRef Chan KM, Yu MC, Wu TJ et al (2009) Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 15:5481–5488PubMedCrossRef
17.
go back to reference Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 431:187–192PubMedCrossRef Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 431:187–192PubMedCrossRef
18.
go back to reference Hoshi M, Taguchi S, Hayakawa K et al (2011) Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary site. Arch Orthop Trauma Surg 131:59–64PubMedCrossRef Hoshi M, Taguchi S, Hayakawa K et al (2011) Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary site. Arch Orthop Trauma Surg 131:59–64PubMedCrossRef
19.
go back to reference Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef
20.
go back to reference Yazawa Y, Frassica FJ, Chao EY et al (1990) Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 251:213–219PubMed Yazawa Y, Frassica FJ, Chao EY et al (1990) Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 251:213–219PubMed
21.
go back to reference Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794–1800PubMedCrossRef Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794–1800PubMedCrossRef
22.
go back to reference Takashi M, Takagi Y, Sakata T et al (1995) Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol 27:1–8PubMedCrossRef Takashi M, Takagi Y, Sakata T et al (1995) Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol 27:1–8PubMedCrossRef
23.
go back to reference Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231PubMedCrossRef Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231PubMedCrossRef
24.
go back to reference Dürr HR, Müller PE, Lenz T et al (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191–196PubMedCrossRef Dürr HR, Müller PE, Lenz T et al (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191–196PubMedCrossRef
Metadata
Title
Prognostic factors for patients with solitary bone metastasis
Authors
Manabu Hoshi
Jun Takada
Makoto Ieguchi
Shinji Takahashi
Hiroaki Nakamura
Publication date
01-02-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0359-3

Other articles of this Issue 1/2013

International Journal of Clinical Oncology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine